Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer

SIMPLE SUMMARY: Aromatase inhibitors (AIs) remain key elements of endocrine therapy for patients with hormone receptor positive HER2 negative metastatic breast cancer (HR(+) HER2(−) MBC). Recent advances include the use of CDK 4/6 inhibitors or PIK3CA inhibitor in the clinic; however, few immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Xuan, Yost, Susan E., Lee, Jin Sun, Frankel, Paul H., Ruel, Christopher, Cui, Yujie, Murga, Mireya, Tang, Aileen, Martinez, Norma, Chung, Samuel, Yeon, Christina, Stewart, Daphne, Li, Daneng, Rajurkar, Swapnil, Somlo, George, Mortimer, Joanne, Waisman, James, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454514/
https://www.ncbi.nlm.nih.gov/pubmed/36077811
http://dx.doi.org/10.3390/cancers14174279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454514/
https://www.ncbi.nlm.nih.gov/pubmed/36077811
http://dx.doi.org/10.3390/cancers14174279

Ejemplares similares